SCHEMBL14994169

SCHEMBL14994169

CC(C)(C)OC(=O)n1nnnc1CCl

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FAAH O00519 3/20 1.00
MAPT P10636 2/20 0.35
ALDH1A1 P00352 3/20 0.34
LMNA P02545 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
HTT P42858 1/20 0.32
ATM Q13315 1/20 0.32
DAGLA Q9Y4D2 2/20 0.32
ELANE P08246 1/20 0.32
MGLL Q99685 2/20 0.31
CTSK P43235 1/20 0.30
HSP90AA1 P07900 1/20 0.30
HSP90AB1 P08238 1/20 0.30
SMN1; SMN2 Q16637 2/20 0.30
USP2 O75604 1/20 0.30
TRPV1 Q8NER1 1/20 0.30
MAP2K4 P45985 1/20 0.30
MEN1 O00255 1/20 0.30
TSHR P16473 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4358478 0.75 FAAH (0.59) FAAHMAPTHTTATMELANE
SCHEMBL6581440 0.73 FAAH (0.58) FAAHMAPTHTTATMELANE
SCHEMBL14994157 0.68 FAAH (0.51) FAAHMAPTALDH1A1HTTATM
SCHEMBL27894052 0.66 FAAH (0.49) FAAHALDH1A1DAGLAMGLLTRPV1
SCHEMBL9933431 0.64 FAAH (0.47) FAAHALDH1A1HTTATMSMN1; SMN2
SCHEMBL31701082 0.64 FAAH (0.47) FAAHMAPTALDH1A1LMNAHTT
SCHEMBL16211963 0.64 ALDH1A1 (0.51) FAAHALDH1A1LMNANPSR1L3MBTL1
SCHEMBL17781345 0.62 FAAH (0.45) FAAHALDH1A1L3MBTL1ELANEHSP90AA1
SCHEMBL15254047 0.61 FAAH (0.43) FAAHMAPTALDH1A1LMNAL3MBTL1
SCHEMBL2490063 0.60 FAAH (0.43) FAAHALDH1A1HTTATMHSP90AA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2785717-B1 PYRAZOLOPYRROLIDINE COMPOUNDS NOVARTIS AG (CH) 2016-01-13 EP disclosed
EP-2785717-B1 PYRAZOLOPYRROLIDINE COMPOUNDS NOVARTIS AG (CH) 2016-01-13 EP disclosed
US-8969341-B2 Pyrazolopyrrolidine compounds NOVARTIS AG (CH) 2015-03-03 US disclosed
US-8969341-B2 Pyrazolopyrrolidine compounds NOVARTIS AG (CH) 2015-03-03 US disclosed
US-8969341-B2 Pyrazolopyrrolidine compounds NOVARTIS AG (CH) 2015-03-03 US disclosed
US-20140350010-A1 Pyrazolopyrrolidine Compounds NOVARTIS AG (CH) 2014-11-27 US disclosed
US-20140350010-A1 Pyrazolopyrrolidine Compounds NOVARTIS AG (CH) 2014-11-27 US disclosed
US-20140350010-A1 Pyrazolopyrrolidine Compounds NOVARTIS AG (CH) 2014-11-27 US disclosed
EP-2785717-A1 PYRAZOLOPYRROLIDINE COMPOUNDS Novartis AG (CH) 2014-10-08 EP disclosed
WO-2013080141-A1 Pyrazolopyrrolidine compounds NOVARTIS AG (CH) 2013-06-06 WO disclosed
WO-2013080141-A1 Pyrazolopyrrolidine compounds NOVARTIS AG (CH) 2013-06-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140350010-A1 Pyrazolopyrrolidine Compounds MDM4, MDM2, TP53 FAAH 4594/4885MAPT 118/4885ALDH1A1 2335/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.